RNA Vaccines and RNA Therapeutics Market: Distribution by Type of Modality (RNA Therapeutics and RNA Vaccines), Type of Molecule (replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA), Therapeutic Areas (Infectious Diseases, Oncological Disorders and Pulmonary Disorders), Route of Administration (Intradermal, Intramuscular and Intravenous), Key Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players: Industry Trends and Global Forecasts, 2023-2035
The global RNA Vaccines and RNA Therapeutics market is expected to reach USD 948 million by 2035 anticipated to grow at a CAGR of 50% during the forecast period 2026-2035.
In recent years, RNA-based therapeutics have become essential in modern healthcare. These treatments play crucial roles in controlling protein production and regulating gene function, offering significant advancements compared to traditional methods. However, concerns persist due to the instability of these molecules and challenges in effectively delivering them at the required concentrations. To tackle these obstacles, various industry stakeholders are actively developing new technologies to enhance the utilization of RNA therapeutics and vaccines. This collective effort holds great promise for improving disease management in healthcare. The evolution of next-gen RNA therapeutics and vaccines involves modifying molecular structures to target diseases that were previously difficult to address pharmaceutically. Innovative modalities like circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA) have gained prominence as targeted therapies. Their success stems from their robust structures, precise targeting in expression, specific delivery mechanisms, lack of immunogenic properties, increased efficacy, and adaptability in addressing diverse therapeutic needs—from managing influenza and COVID-19 to conditions like breast cancer and interstitial lung disease.
Moreover, due to their self-replicating nature, these RNA-based treatments provide extended therapeutic effects at lower and less frequent doses compared to conventional methods. Continuous innovation, promising clinical trial results, expedited regulatory approvals, and collaborative efforts between industry and non-industry players are expected to drive significant growth in the next-gen RNA vaccines and therapeutics market in the coming years.
Report Coverage
In recent years, RNA-based therapeutics have become essential in modern healthcare. These treatments play crucial roles in controlling protein production and regulating gene function, offering significant advancements compared to traditional methods. However, concerns persist due to the instability of these molecules and challenges in effectively delivering them at the required concentrations. To tackle these obstacles, various industry stakeholders are actively developing new technologies to enhance the utilization of RNA therapeutics and vaccines. This collective effort holds great promise for improving disease management in healthcare. The evolution of next-gen RNA therapeutics and vaccines involves modifying molecular structures to target diseases that were previously difficult to address pharmaceutically. Innovative modalities like circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA) have gained prominence as targeted therapies. Their success stems from their robust structures, precise targeting in expression, specific delivery mechanisms, lack of immunogenic properties, increased efficacy, and adaptability in addressing diverse therapeutic needs—from managing influenza and COVID-19 to conditions like breast cancer and interstitial lung disease.
Moreover, due to their self-replicating nature, these RNA-based treatments provide extended therapeutic effects at lower and less frequent doses compared to conventional methods. Continuous innovation, promising clinical trial results, expedited regulatory approvals, and collaborative efforts between industry and non-industry players are expected to drive significant growth in the next-gen RNA vaccines and therapeutics market in the coming years.
Report Coverage
- The report extensively investigates the antibiotics market based on type of modality, type of molecule, therapeutic areas, route of administration, key geographical regions
- It analyzes market growth by examining factors such as drivers, restraints, opportunities, and challenges.
- Evaluation of potential advantages and barriers within the market landscape is provided, along with insights into the competitive environment for leading market players.
- Revenue forecasts for market segments across three major regions are presented.
- Introduction of a comprehensive report on the RNA Therapeutics and RNA Vaccines Market, 2023-2035, detailing the rigorous research methodology employed to ensure precision and reliability, including insights into assumptions, methodologies, and quality control measures.
- Exploration of economic factors impacting the next generation of RNA therapeutics and RNA vaccines market, encompassing historical trends, currency fluctuations, foreign exchange impacts, recessionary influences, and measures of inflation.
- Summary of research insights, offering a high-level perspective on the current state and anticipated evolution of the next generation RNA therapeutics and RNA vaccines market in the mid-to-long term.
- Brief overview of the historical background and core elements of next-generation RNA therapeutics and vaccines, highlighting types, key challenges, and advantages of employing these modalities.
- Comprehensive assessment of over 100 RNA therapeutics and vaccines, including approved and developmental stages, categorized by modality, molecule type, delivery vehicle, development phases, therapeutic areas, and niche market segments.
- Examination of more than 35 technologies supporting RNA therapeutics and vaccines development, considering class, molecule type, technological capabilities, therapeutic areas, and developmental phases, and profiling technology developers based on establishment, company size, and operational model.
- Detailed profiles of Phase II, III, and beyond drug candidates, providing insights into developers, drug overviews, clinical trial information, endpoints, results, and estimated sales.
- In-depth examination of completed and ongoing clinical trials, considering parameters such as registration year, trial status, phases, enrolled patients, sponsors, therapeutic areas, study designs, leading organizations, focus areas, and geography.
- Comprehensive review of patents related to RNA therapeutics and vaccines filed/granted since 2019, focusing on patent types, publication years, jurisdictions, CPC symbols, emerging focus areas, leading patent holders, and valuation.
- Thorough analysis of partnerships among stakeholders since 2019, considering partnership types, molecules, focus, purpose, therapeutic areas, active players, and regional distribution of partnership activities.
- Detailed scrutiny of investments in the industry since 2019, analyzing funding types, amounts, geographies, purposes, developmental stages, therapeutic areas, active players, and leading investors.
- In-depth examination of initiatives by major pharmaceutical companies, considering the number, year, type, purpose, focus, and locations of these initiatives in the realm of next-generation RNA therapeutics and vaccines.
- Alphavax
- Arcturus Therapeutics
- Atyr Pharma
- Gritstone Bio
- HDT Bio
- MiNA Therapeutics
- VLP Therapeutics
1. PREFACE
1.1. RNA Therapeutics and RNA Vaccines Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities
6. MARKET LANDSCAPE
6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies
7. TECHNOLOGY LANDSCAPE
7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model
8. DRUG PROFILES
8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.2.1. Developer Overview
8.2.2. Drug Overview
8.2.3. Clinical Trial Information
8.2.4. Clinical Trial Endpoints
8.2.5. Clinical Trial Results
8.2.6. Estimated Sales
8.3. ARCT-154
8.3.1. Developer Overview
8.3.2. Drug Overview
8.3.3. Clinical Trial Information
8.3.4. Clinical Trial Endpoints
8.3.5. Clinical Trial Results
8.3.6. Estimated Sales
8.4. GRT-C901
8.4.1. Developer Overview
8.4.2. Drug Overview
8.4.3. Clinical Trial Information
8.4.4. Clinical Trial Endpoints
8.4.5. Clinical Trial Results
8.4.6. Estimated Sales
8.5. VLPCOV-01
8.5.1. Developer Overview
8.5.2. Drug Overview
8.5.3. Estimated Sales
8.6. AVX901
8.6.1. Developer Overview
8.6.2. Drug Overview
8.6.3. Clinical Trial Information
8.6.4. Clinical Trial Endpoints
8.6.5. Clinical Trial Results
8.6.6. Estimated Sales
8.7. MTL-CEBPA + Sorafenib
8.7.1. Developer Overview
8.7.2. Drug Overview
8.7.3. Clinical Trial Information
8.7.4. Clinical Trial Endpoints
8.7.5. Clinical Trial Results
8.7.6. Estimated Sales
8.8. SLATE
8.8.1. Developer Overview
8.8.2. Drug Overview
8.8.3. Clinical Trial Information
8.8.4. Clinical Trial Endpoints
8.8.5. Clinical Trial Results
8.8.6. Estimated Sales
9. CLINICAL TRIAL ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography
10. PATENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances
13. BIG PHARMA INITIATIVES
13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players
14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035
14.1. Key Assumptions and Methodology
14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard
15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY
15.1. Therapeutics: Forecasted Estimates (2023-2035)
15.2. Vaccines: Forecasted Estimates (2023-2035)
15.3. Data Triangulation and Validation
16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE
16.1. repRNA: Forecasted Estimates (2023-2035)
16.2. saRNA: Forecasted Estimates (2023-2035)
16.3. sacRNA: Forecasted Estimates (2023-2035)
16.4. sa-mRNA: Forecasted Estimates (2023-2035)
16.5. tRNA: Forecasted Estimates (2023-2035)
16.6. Data Triangulation and Validation
17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA
17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation
18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation
19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. North America: Forecasted Estimates (2023-2035)
19.1.1. US: Forecasted Estimates (2023-2035)
19.2. Europe: Forecasted Estimates (2023-2035)
19.2.1. France: Forecasted Estimates (2023-2035)
19.2.2. Italy: Forecasted Estimates (2023-2035)
19.2.3. Spain: Forecasted Estimates (2023-2035)
19.2.4. UK: Forecasted Estimates (2023-2035)
19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
19.3.1. India: Forecasted Estimates (2023-2035)
19.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3. Singapore: Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation
20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS
20.1. Company A
20.2. Company B
20.3. Company C
20.4. Company D
20.5. Company E
21. CONCLUSION
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. RNA Therapeutics and RNA Vaccines Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities
6. MARKET LANDSCAPE
6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies
7. TECHNOLOGY LANDSCAPE
7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model
8. DRUG PROFILES
8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.2.1. Developer Overview
8.2.2. Drug Overview
8.2.3. Clinical Trial Information
8.2.4. Clinical Trial Endpoints
8.2.5. Clinical Trial Results
8.2.6. Estimated Sales
8.3. ARCT-154
8.3.1. Developer Overview
8.3.2. Drug Overview
8.3.3. Clinical Trial Information
8.3.4. Clinical Trial Endpoints
8.3.5. Clinical Trial Results
8.3.6. Estimated Sales
8.4. GRT-C901
8.4.1. Developer Overview
8.4.2. Drug Overview
8.4.3. Clinical Trial Information
8.4.4. Clinical Trial Endpoints
8.4.5. Clinical Trial Results
8.4.6. Estimated Sales
8.5. VLPCOV-01
8.5.1. Developer Overview
8.5.2. Drug Overview
8.5.3. Estimated Sales
8.6. AVX901
8.6.1. Developer Overview
8.6.2. Drug Overview
8.6.3. Clinical Trial Information
8.6.4. Clinical Trial Endpoints
8.6.5. Clinical Trial Results
8.6.6. Estimated Sales
8.7. MTL-CEBPA + Sorafenib
8.7.1. Developer Overview
8.7.2. Drug Overview
8.7.3. Clinical Trial Information
8.7.4. Clinical Trial Endpoints
8.7.5. Clinical Trial Results
8.7.6. Estimated Sales
8.8. SLATE
8.8.1. Developer Overview
8.8.2. Drug Overview
8.8.3. Clinical Trial Information
8.8.4. Clinical Trial Endpoints
8.8.5. Clinical Trial Results
8.8.6. Estimated Sales
9. CLINICAL TRIAL ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography
10. PATENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances
13. BIG PHARMA INITIATIVES
13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players
14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035
14.1. Key Assumptions and Methodology
14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard
15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY
15.1. Therapeutics: Forecasted Estimates (2023-2035)
15.2. Vaccines: Forecasted Estimates (2023-2035)
15.3. Data Triangulation and Validation
16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE
16.1. repRNA: Forecasted Estimates (2023-2035)
16.2. saRNA: Forecasted Estimates (2023-2035)
16.3. sacRNA: Forecasted Estimates (2023-2035)
16.4. sa-mRNA: Forecasted Estimates (2023-2035)
16.5. tRNA: Forecasted Estimates (2023-2035)
16.6. Data Triangulation and Validation
17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA
17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation
18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation
19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. North America: Forecasted Estimates (2023-2035)
19.1.1. US: Forecasted Estimates (2023-2035)
19.2. Europe: Forecasted Estimates (2023-2035)
19.2.1. France: Forecasted Estimates (2023-2035)
19.2.2. Italy: Forecasted Estimates (2023-2035)
19.2.3. Spain: Forecasted Estimates (2023-2035)
19.2.4. UK: Forecasted Estimates (2023-2035)
19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
19.3.1. India: Forecasted Estimates (2023-2035)
19.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3. Singapore: Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation
20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS
20.1. Company A
20.2. Company B
20.3. Company C
20.4. Company D
20.5. Company E
21. CONCLUSION
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
